S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:SNDX

Syndax Pharmaceuticals - SNDX Stock Forecast, Price & News

$21.12
+0.46 (+2.23%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$20.66
$21.43
50-Day Range
$20.66
$28.98
52-Week Range
$13.27
$29.86
Volume
2.02 million shs
Average Volume
931,768 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.57

Syndax Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
59.0% Upside
$33.57 Price Target
Short Interest
Bearish
9.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$4.06 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.04) to ($3.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

197th out of 996 stocks

Pharmaceutical Preparations Industry

81st out of 484 stocks


SNDX stock logo

About Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Stock News Headlines

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 4%
Stocks are for suckers – try this instead
This has nothing to do with dividends, day trading... taking out a loan... or anything like that. What you need is about 3 seconds to execute this simple financial maneuver...
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
See More Headlines
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Company Calendar

Last Earnings
2/28/2023
Today
4/01/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNDX
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.57
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+59.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-149,340,000.00
Pretax Margin
-11.02%

Debt

Sales & Book Value

Annual Sales
$139.71 million
Book Value
$7.76 per share

Miscellaneous

Free Float
64,131,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
1.04

Key Executives

  • Michael A. MetzgerMichael A. Metzger
    Chief Executive Officer & Director
  • Briggs W. MorrisonBriggs W. Morrison
    President & Director
  • Keith Alan Goldan
    Chief Financial Officer & Treasurer
  • Peter OrdentlichPeter Ordentlich
    Chief Scientific Officer
  • Catherine Madigan
    Chief Medical Officer













SNDX Stock - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings
or view top-rated stocks.

What is Syndax Pharmaceuticals' stock price forecast for 2023?

6 brokerages have issued twelve-month target prices for Syndax Pharmaceuticals' shares. Their SNDX share price forecasts range from $31.00 to $37.00. On average, they expect the company's stock price to reach $33.57 in the next year. This suggests a possible upside of 59.0% from the stock's current price.
View analysts price targets for SNDX
or view top-rated stocks among Wall Street analysts.

How have SNDX shares performed in 2023?

Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of 2023. Since then, SNDX stock has decreased by 17.0% and is now trading at $21.12.
View the best growth stocks for 2023 here
.

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our SNDX earnings forecast
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its quarterly earnings results on Tuesday, February, 28th. The company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02.

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $21.12.

How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.45 billion and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420.

This page (NASDAQ:SNDX) was last updated on 4/2/2023 by MarketBeat.com Staff